Your browser doesn't support javascript.
Kidney Transplantation during the Three Years (2020-2022) of Covid-19 Pandemic: Single-Center Experience
Kidney International Reports ; 8(3 Supplement):S459, 2023.
Article in English | EMBASE | ID: covidwho-2266950
ABSTRACT

Introduction:

During the first year of coronavirus disease (COVID)-19 outbreak, kidney transplant programs were suspended in several countries in the World. Republic of Belarus did not suspend organ transplant program carefully weighed the risks and benefits of pursuing or postponing kidney transplantation. In cooperation with national-level efforts, our transplant program adopted universal donor and recipient screening using reverse transcriptase polymerase chain reaction for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) with or without chest CT scans before kidney transplantation. Thus, national kidney transplant activities in Republic of Belarus remained stable for both living and deceased donor transplantation compared with the same period during the previous year. The objective was to study the safety of kidney transplantation, the incidence of COVID-19 disease in kidney transplant patients and medical care providing for transplanted patients during this pandemic period. Method(s) A retrospective review of all patients who had received a kidney transplant at State Institution "Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology" in Minsk, Republic of Belarus was performed from January 2020 to November 2022. Result(s) Dynamics of kidney transplantations number, clinical data of recipients during 3 years Covid-19 pandemic compared with the previous year are presented in table 1. The rate of infection in early postoperative period was low 1,1% (2020), 0,5% (2021) and 0% (November 2022). In case of SARS-CoV2 infection modifications of immunosuppression (IS) therapy were based on the clinical conditions. For asymptomatic patients "wait and see approach" was mostly used;a suspension of antimetabolites drugs was adopted in the majority of patients with symptomatic COVID-19 infections. For CNIs, withdrawal was the preferred choice in severely symptomatic patients. A discontinuation of all IS drugs was used only in severely symptomatic COVID-19 patients on invasive mechanical ventilation. Since 2022 we started to use remdesivir in recipients with symptomatic course of disease with positive results. [Formula presented] From the middle of 2021 we commenced specific vaccination among transplanted patients. Most widely available vaccines in Belarus were CoronaVac (Sinovac Life Sciences, Beijing, China) and Gam-COVID-Vac (Gamaleya Research Institute of Epidemiology and Microbiology, Russia). There were no revealed any adverse effects of vaccination among our group. Conclusion(s) In our experience, the current kidney transplant program seems viable and safe, even during periods of health emergencies. No conflict of interestCopyright © 2023
Keywords

Full text: Available Collection: Databases of international organizations Database: EMBASE Language: English Journal: Kidney International Reports Year: 2023 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: Databases of international organizations Database: EMBASE Language: English Journal: Kidney International Reports Year: 2023 Document Type: Article